TrialAnnals of the rheumatic diseases2009

Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study.

N Nishimoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.